Navigation Links
Initial Studies of Channel Medsystems' Cryothermic Therapy Demonstrate Preliminary Safety and Tolerability; Results Presented at the 42nd AAGL Global Congress

SAN FRANCISCO, Nov. 21, 2013 /PRNewswire/ -- Results from histopathology and initial tolerability studies of Channel Medsystems' novel technology for endometrial ablation were presented at last week's AAGL Global Congress in Washington, D.C. The findings represent a first indication of the safety and effectiveness of this device, which is intended for use in the treatment of heavy menstrual bleeding, a condition that affects one in five women in the United States.  The published data demonstrate that the Company's cryothermic therapy had preliminary safety, created a favorable ablation profile, and was well-tolerated by subjects.  Evidence from these initial studies forms the foundation of a data set designed to prove that Channel Medsystem's device is an appropriate technology for the physician office setting.


These initial studies were performed in subjects undergoing a planned hysterectomy. Histopathology data from these studies were analyzed by Dr. James Coad, a pathologist from West Virginia University and co-author of the published data.

The studies demonstrated that Channel Medsystems' cryothermic therapy (1) had an acceptable safety profile, (2) can be performed in a clinically appropriate timeframe, and (3) was well-tolerated by the subject without the need for general anesthesia or conscious sedation.  In addition, evaluation of the removed uteri revealed excellent cavity coverage and an ablation profile that mirrors currently-available hyperthermic therapies.  "This procedure appears to facilitate an appropriate depth of ablation of the endometrium, from a full-thickness ablation of the body of the uterus to a thinner ablation that is desirable in the cornua and lower uterine segment," said Dr. Coad.  "The precision in the depth of ablation is a key factor in achieving an effective outcome without compromising the function of the underlying uterine tissue."

"These results are promising and indicate that our cryothermic therapy is ready for the next stage of evaluation," said Ric Cote, President and CEO of Channel Medsystems.  "We are looking forward to beginning enrollment in our Cryoablation Feasibility Trial (CRYSTAL), where we will focus on assessing outcomes in women with heavy menstrual bleeding up to six months after the procedure."  The CRYSTAL study is designed to further evaluate the effectiveness and tolerability of Channel Medsystems' in-office cryothermic procedure at leading centers in Canada and will begin enrollment this month.

About the Cryothermic Technology Platform: Channel Medsystems' novel cryothermic technology and streamlined delivery system were developed with feedback from leading clinicians and biomedical engineers at the healthcare incubator, Theranova. The technology integrates cryothermic energy and the user controls into a self-contained, handheld device, eliminating the need for a separate control unit or capital equipment.

About Channel Medsystems:  Channel Medsystems is a venture-backed company that was founded to bring innovation to the delivery of women's healthcare. The Company strives to develop treatments to meet the unique needs of female patients and the high standards of their healthcare providers. Channel Medsystems is committed to ensuring that patients have access to high quality outcomes that can be delivered in the convenience and comfort of their healthcare provider's office. For more information, please visit

CAUTION: This device is available for investigational use in Canada.  It is not available for sale or investigational use in the United States.

SOURCE Channel Medsystems
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Montage Healthcare and Mammography Reporting Systems to show initial results of partnership to enrich mammography quality efforts at RSNA 2013
2. Tandem Diabetes Care Announces Closing of Initial Public Offering
3. Tandem Diabetes Care Announces Exercise of Option to Purchase Additional Shares in Initial Public Offering of Common Stock
4. Epizymes EPZ-5676 DOT1L Inhibitor Demonstrates Encouraging Initial Findings in an Ongoing Phase 1 Dose Escalation Study
5. Tandem Diabetes Care Prices Initial Public Offering
6. American Red Cross Contributes an Initial $6 Million to Support Typhoon Haiyan Response Efforts in Philippines
7. Cara Therapeutics Files Registration Statement for Proposed Initial Public Offering
8. Veracyte, Inc. Announces Pricing of Initial Public Offering
9. Genocea Reports Positive Initial Phase 1/2a Results for GEN-003, its Pioneering Therapeutic Vaccine Candidate for the Treatment of Herpes Simplex Virus-2 (HSV-2), at ICAAC 2013
10. Regado Biosciences, Inc. Announces Closing of Initial Public Offering
11. Regado Biosciences, Inc. Announces Pricing of Initial Public Offering
Post Your Comments:
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
(Date:11/25/2015)... AAIPharma Services Corp./Cambridge Major Laboratories, Inc. ... $15.8  Million to expand its laboratories and global ... The expansion will provide additional office space and ... of the pharmaceutical and biotechnology markets. ... up to 40,000 square feet of expanded development ...
(Date:11/25/2015)... Nov. 25, 2015  Henry Schein, Inc., the world,s ... office-based dental, medical and animal health practitioners, will unveil ... Henry Schein ConnectDental® Pavilion , which brings together ... open solutions designed to help any practice or laboratory ... for a schedule of experts appearing at the ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions announced ... User Group (MSDSLUG). Recognized as Microsoft’s official group for end users of Dynamics ... software users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates their ...
(Date:11/27/2015)... ... 27, 2015 , ... The men and women on this ... in the country. They have overseen financial turnarounds, shown commitment to their community ... industry as a whole through their advocacy and professional efforts. , Becker's Hospital ...
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think Thanksgiving, they also think ... during the Black Friday and Cyber Monday massage chair sales to receive ... high and low to find the best massage chair deals, they can see all ...
(Date:11/26/2015)... Antonio, TX (PRWEB) , ... November 26, 2015 , ... ... On November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction ... , “We wake up every day excited to rebuild lives and it’s an honor ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... than those found on mammography, according to a study published online in the ... not seen on mammography may necessitate a change in treatment. , Breast MRI ...
Breaking Medicine News(10 mins):